Despite Gilead’s Promising HIV Prevention Drug, A Vaccine Is Still The ‘Holy Grail’

HIV Nouvelles

Despite Gilead’s Promising HIV Prevention Drug, A Vaccine Is Still The ‘Holy Grail’
AIDSGileadPrep
  • 📰 ForbesTech
  • ⏱ Reading Time:
  • 56 sec. here
  • 9 min. at publisher
  • 📊 Quality Score:
  • News: 50%
  • Publisher: 59%

Katie Jennings is a senior writer at Forbes covering healthcare, technology and AI and a co-author of the InnovationRX newsletter. She joined Forbes in 2020 and is based in Jersey City.

The U.N. has proposed a target of ending AIDS by 2030. But it’s a pipe dream unless scientists are able to crack the code of one of the world’s sneakiest viruses and develop an effective vaccine.“Until there’s a cure or a vaccine, we will need to sustain the AIDS response beyond 2030,” UN AIDS Executive Director Winnie Byanyima said last month.

Around 39.9 million people worldwide are living with HIV and there are an estimated 1.3 million new infections each year, with cases rising in the Middle East and North Africa, Eastern Europe, central Asia and Latin America, according to theacknowledges “the world is off track.

There are several big challenges with HIV that boil down to the same principle: it’s a very sneaky escape artist that is constantly changing and using decoys to evade capture by the immune system. The usual approach for many vaccines is to introduce inactivated virus or pieces of virus into the body so that the immune system can prepare a response in advance of infection.

He likens the current efforts by scientists working on multiple types of vaccine responses to top-secret World War II codebreakers in England’s Bletchley Park. “You're trying to solve something that's unknown, and you're getting together the best minds to figure out how to decode the enigma machines,” said Yang, though he is not confident that an HIV vaccine is currently possible without a major breakthrough.

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

ForbesTech /  🏆 318. in US

AIDS Gilead Prep Lenacapavir Vaccine UNAIDS AIDS24

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

Despite roster turnover, analytics are promising for 2024-25 GophersSome people think Minnesota got better this offseason.
Lire la suite »

California Goes Off The Rails—AgainCalifornia Goes Off The Rails—AgainSteve Forbes is Chairman and Editor-in-Chief of Forbes Media.
Lire la suite »

China Still Beckons This Successful Venture CapitalistChina Still Beckons This Successful Venture CapitalistRussell Flannery is an editor at large at Forbes and a country editor for the Forbes Billionaires List. Now in his 24th year at Forbes, Flannery opened Forbes first-ever bureau in mainland China -- in Shanghai – in 2003.
Lire la suite »

China Fund Aims To Get Tech Scholars More Involved In EntrepreneurshipChina Fund Aims To Get Tech Scholars More Involved In EntrepreneurshipRussell Flannery is an editor at large at Forbes and a country editor for the Forbes Billionaires List. Now in his 24th year at Forbes, Flannery opened Forbes first-ever bureau in mainland China -- in Shanghai – in 2003.
Lire la suite »

The One Reason Warren Buffett Isn’t The World’s Richest PersonThe One Reason Warren Buffett Isn’t The World’s Richest PersonChase Peterson-Withorn is a senior editor at Forbes who oversees The Forbes 400 list. His reporting on billionaires has stretched from America's largest cardboard box factory to Donald Trump's penthouse. He studied political science and economics at Ohio University, and can be reached at cpeterson-withornforbes.com or tipsforbes.com.
Lire la suite »

X-Men '97 Gets A Promising New Season 3 UpdateX-Men '97 Gets A Promising New Season 3 UpdateX-Men &39;97 Gets A Promising New Season 3 Update
Lire la suite »



Render Time: 2025-02-25 11:14:41